These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 4832585)
21. Gout: joint pain and more. Harv Mens Health Watch; 2007 Dec; 12(5):1-3. PubMed ID: 18225332 [No Abstract] [Full Text] [Related]
22. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941 [TBL] [Abstract][Full Text] [Related]
23. [Independent risk factors for severe cardiovascular events in male patients with gout: Results of a 7-year prospective study]. Eliseev MS; Denisov IS; Markelova EI; Glukhova SI; Nasonov EL Ter Arkh; 2017; 89(5):10-19. PubMed ID: 28631693 [TBL] [Abstract][Full Text] [Related]
31. [Urolithiasis in gout and hyperuricemic syndrome]. Vachtenheim J; Srámek F Beitr Rheumatol; 1972; 18():56-60. PubMed ID: 4649119 [No Abstract] [Full Text] [Related]
32. [Allopurinol in the treatment of gout: initial results]. Serre H; Simon L; Claustre J Rev Rhum Mal Osteoartic; 1968 Jun; 35(6):334-44. PubMed ID: 5701049 [No Abstract] [Full Text] [Related]
33. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report. Templeton JS Br J Clin Pract; 1982 Oct; 36(10):353-8. PubMed ID: 7171423 [No Abstract] [Full Text] [Related]
34. Urate nephropathy. Foley RJ; Weinman EJ Am J Med Sci; 1984 Dec; 288(5):208-11. PubMed ID: 6393761 [No Abstract] [Full Text] [Related]
35. Excellent response to the clinical treatment of tophaceous gout. Caldas CA; Fuller R Clin Rheumatol; 2007 Sep; 26(9):1553-5. PubMed ID: 17047891 [TBL] [Abstract][Full Text] [Related]
36. The Effect of Allopurinol on Renal Function. Krishnamurthy A; Lazaro D; Stefanov DG; Blumenthal D; Gerber D; Patel S J Clin Rheumatol; 2017 Jan; 23(1):1-5. PubMed ID: 28002149 [TBL] [Abstract][Full Text] [Related]
37. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. van Lieshout-Zuidema MF; Breedveld FC J Rheumatol; 1993 Aug; 20(8):1383-5. PubMed ID: 8230024 [TBL] [Abstract][Full Text] [Related]
38. Allopurinol in treatment of patients with gout and chronic renal failure. Bowie EA; Simmonds HA; North JD N Z Med J; 1967 Sep; 66(421):606-11. PubMed ID: 5234549 [No Abstract] [Full Text] [Related]
39. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Goicoechea M; Garcia de Vinuesa S; Verdalles U; Verde E; Macias N; Santos A; Pérez de Jose A; Cedeño S; Linares T; Luño J Am J Kidney Dis; 2015 Apr; 65(4):543-9. PubMed ID: 25595565 [TBL] [Abstract][Full Text] [Related]
40. [Clinical findings and therapy of gout with special reference to the metabolic effects of sulfinpyrazone (Anturan) and allopurinol (Zyloric)]. Günther R; Knapp E Wien Klin Wochenschr; 1969 Nov; 81(45):817-20. PubMed ID: 5362152 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]